Q2 Earnings Estimate for FATE Issued By Leerink Partnrs
Fate Therapeutics, Inc. (NASDAQ:FATE – Free Report) – Equities research analysts at Leerink Partnrs issued their Q2 2025 earnings per share (EPS) estimates for shares of Fate Therapeutics in a report issued on Wednesday, May 14th. Leerink Partnrs analyst D. Graybosch forecasts that the biopharmaceutical company will earn ($0.36) per share for the quarter. The […]
Fate Therapeutics, Inc. (NASDAQ:FATE – Free Report) – Equities research analysts at Leerink Partnrs issued their Q2 2025 earnings per share (EPS) estimates for shares of Fate Therapeutics in a report issued on Wednesday, May 14th. Leerink Partnrs analyst D. Graybosch forecasts that the biopharmaceutical company will earn ($0.36) per share for the quarter. The […]
